Torna al Registre Simple

 

Circulating pyruvate is a potent prognostic marker for critical COVID-19 outcomes

dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCeperuelo Mallafré, Victòria
dc.contributor.authorPeraire, Joaquim
dc.contributor.authorMadeira, Ana
dc.contributor.authorMaymó Masip, Elsa
dc.contributor.authorLópez-Dupla, Miguel
dc.contributor.authorBuzón Gómez, María José
dc.contributor.authorReverté Calvet, Laia
dc.date.accessioned2022-12-19T08:54:32Z
dc.date.available2022-12-19T08:54:32Z
dc.date.issued2022-09-14
dc.identifier.citationCeperuelo-Mallafré V, Reverté L, Peraire J, Madeira A, Maymó-Masip E, López-Dupla M, et al. Circulating pyruvate is a potent prognostic marker for critical COVID-19 outcomes. Front Immunol. 2022 Sep 14;13:912579.
dc.identifier.issn1664-3224
dc.identifier.urihttps://hdl.handle.net/11351/8681
dc.descriptionCOVID-19; Quantificació fluoromètrica; Piruvat
dc.description.sponsorshipThis work has been developed in the framework of the COVIDOMICS’ project supported by Direcció General de Recerca i Innovació en Salut (DGRIS), Departament de Salut, Generalitat de Catalunya (PoC-6-17 and PoC1-5). The research was also funded by the Programa de Suport als Grups de Recerca AGAUR (2017SGR948), the SPANISH AIDS Research Network [RD16/0025/0006]-ISCIII-FEDER (Spain) and the Centro de Investigación Biomédica en Red de Enfermedades Infecciosas-ISCIII [CB21/13/00020], Madrid, Spain. LR is supported by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CD20/00105” through the program “Contratos Sara Borrell”. FV is supported by grants from the Programa de Intensificación de Investigadores (INT20/00031)-ISCIII and by “Premi a la Trajectòria Investigadora dels Hospitals de l’ICS 2018”. AR is supported by a grant from IISPV through the project “2019/IISPV/05” (Boosting Young Talent), by GeSIDA through the “III Premio para Jóvenes Investigadores 2019” and by the Instituto de Salud Carlos III (ISCIII) under grant agreement “CP19/00146” through the Miguel Servet Program. This study was also supported by grants SAF2015–65019-R and RTI2018–093919-B-100 (to SF-V.) funded by MCIN/AEI and by “ERFD A way of making Europe”; PI19/01337 to FV, PI20/00095 to VC.-M, PI20/00326 to AR and PI20/00338 to JV funded by ISCIII, cofinanced by the European Regional Development Fund (ERDF), and from Fundación Bancaria Caixa d’Estalvis i Pensions de Barcelona (HR20-00051 to SF-V). The Spanish Biomedical Research Center in Diabetes and Associated Metabolic Disorders (CIBERDEM) (CB07708/0012) is an initiative of the Instituto de Salud Carlos III. SF-V acknowledges support from the Miguel Servet tenure-track program (CP10/00438 and CPII16/00008) from the Fondo de Investigación Sanitaria, cofinanced by the ERDF. VC-M acknowledges support from the Ramón y Cajal program (RYC2019-026490-I) from the Spanish Ministry of Science and Innovation, cofinanced by the ERDF. The work was also supported by Consejeria de Salud y Familia (COVID-0005-2020), Consejeria de Transformacion Economica, Industria, Conocimiento y Universidades Junta de Andalucia (CV20-85418to ER-M) and Instituto de Salud Carlos III (ISCIII) under grant agreement CP19/00159 to AGV “a way to make Europe”. ER-M was supported by the Spanish Research Council (CSIC). The funders have no roles in study design, data collection, data analysis, interpretation or the writing of this research.
dc.language.isoeng
dc.publisherFrontiers Media
dc.relation.ispartofseriesFrontiers in Immunology;13
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia)
dc.subjectMarcadors bioquímics
dc.subjectPrognosi
dc.subject.meshCoronavirus Infections
dc.subject.meshPrognosis
dc.subject.meshBiomarkers
dc.subject.meshPyruvic Acid
dc.titleCirculating pyruvate is a potent prognostic marker for critical COVID-19 outcomes
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3389/fimmu.2022.912579
dc.subject.decsinfecciones por Coronavirus
dc.subject.decspronóstico
dc.subject.decsbiomarcadores
dc.subject.decsácido pirúvico
dc.relation.publishversionhttps://doi.org/10.3389/fimmu.2022.912579
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Ceperuelo-Mallafré V] Universitat Rovira i Virgili (URV), Tarragona, Spain. Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)- Instituto de Salud Carlos III, Madrid, Spain. [Reverté L] Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. CIBER Enfermedades Infecciosas (CIBERINFEC)- Instituto de Salud Carlos III, Madrid, Spain. [Peraire J, López-Dupla M] Universitat Rovira i Virgili (URV), Tarragona, Spain. Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. CIBER Enfermedades Infecciosas (CIBERINFEC)- Instituto de Salud Carlos III, Madrid, Spain. Hospital Universitari de Tarragona Joan XXIII (HJ23), Tarragona, Spain. [Madeira A, Maymó-Masip E] Institut Investigació Sanitària Pere Virgili (IISPV), Tarragona, Spain. CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM)- Instituto de Salud Carlos III, Madrid, Spain. [Buzón MJ] Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Servei de Malalties Infeccioses, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain
dc.identifier.pmid36189213
dc.identifier.wos000861817200001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Portada del document
Name:
circulating_pyruvate_a_potent_ ...
Grandària:
1.247Mb
Format:
PDF
Description:
Circulating pyruvate is a potent ...
Visualitza

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple